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Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature. 
Abstract:  
Background: Active surveillance is an increasingly prevalent treatment choice for low-grade prostate cancer.  The 
eligibility criteria for active surveillance are varied and it is unclear if family history of prostate cancer should be 
used as an exclusion criterion when considering men for active surveillance treatment. 
Objective: To determine whether family history plays a significant role in the progression of prostate cancer for men 
undergoing active surveillance. 
Methods: PubMed searches of “family history and prostate cancer”, “family history and prostate cancer progression” 
and “factors of prostate cancer progression” were used to identify research publications about the relationship 
between family history and prostate cancer progression.  These searches generated 536 papers that were screened 
and reviewed.  Six publications were ultimately included in this analysis.  
Results: Review of six publications suggests that family history does not increase the risk of prostate cancer 
progression.  Six studies found that family history does not increase the risk of prostate cancer progression, while 
one study found that family history increases the risk of prostate cancer progression only in African Americans.   
Conclusion: A family history of prostate cancer does not appear to increase a patient’s risk of having more 
aggressive prostate cancer and is therefore unlikely to be an important factor in determining eligibility for active 
surveillance.  Further studies are needed to better understand the relationship between race, family history, and 
eligibility for active surveillance. 
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Introduction:  
Prostate cancer is the second most common cancer in American men1.  One in seven men will be diagnosed with 
prostate cancer during his lifetime1; however, the aggressiveness of the disease can vary between patients allowing 
for different treatment options.  Men with highly aggressive prostate cancer typically receive treatment while active 
surveillance is an option for patients with lower-risk, less-aggressive cancer.  Different centers have proposed 
different criteria to guide clinicians in determining the eligibility of a patient for active surveillance.  Commonly 
used criteria include low grade and low volume tumor on biopsy and low PSA2.   
There are multiple studies suggesting that a family history of prostate cancer increases an individual’s risk of 
developing prostate cancer; however, it is unclear if family history should be included as an eligibility criterion for 
active surveillance.  Herein, we performed a systematic review of all available literature regarding the possible 
relationship between family history and prostate cancer progression and eligibility for active surveillance.  These 
results will have implications for providers and policy makers as they consider the impact that family history could 
have on the implementation of active surveillance. 
Objective and Methods:  
Our objective was to review relevant literature to assess whether a family history of prostate cancer was associated 
with prostate cancer progression and therefore should be included in the criteria for selecting patients for 
consideration of active surveillance.  No review protocol exists for the topic, so we searched PubMed using terms of 
“family history and prostate cancer”, “family history and prostate cancer progression”, and “factors of prostate 
cancer progression” to identify published English-language studies that evaluated the relationship between prostate 
cancer progression or aggressiveness of disease and family history.  We aimed to identify publications that evaluated 
family history among patients eligible for or on active surveillance protocols. 
The searches were performed in March 2016 and generated 536 publications.  These were screened first by titles and 
then by reviewing abstracts.  Of the 536 publications, 464 publications were excluded because they were not focused 
on prostate cancer progression or eligibility for active surveillance.  Sixty-six publications were then excluded 
because they were commentaries rather than primary research publications. This resulted in six candidate 
publications.  References of these six publications were reviewed to identify additional publications and none were 
found.  Therefore, a total of six publications were included in this systematic review (Figure 1).  Two independent 
assessors (JMT and JMD) evaluated the papers.  The principle summary measure was the p-value that evaluated the 
clinical risk for aggressive prostate cancer in participants with and without a family history of prostate cancer. There 
was a risk of bias from the limited number of studies and participants, so results were not pooled. Institutional 
Review Board approval was not required since this was an analysis of previously reported, publically available 
literature. 
Results:  
We identified six publications reporting on the relationship between family history and prostate cancer progression 
in patients eligible for or on active surveillance (Table 1).   
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All six observational studies of men found no relationship between family history and prostate cancer progression. 
Four studies used pathologic features to determine progression and progression was defined by a change to adverse, 
more aggressive pathology.  Two studies used biomarkers such as prostate cancer antigen three (PCA3), 
transmembrane protease, serine 2 (TMPRSS2-ERG), and prostate specific antigen (PSA) to determine prostate 
cancer aggressiveness. 
Impact of family history on pathologic findings 
In a study by Selkirk and colleagues, 200 patients were categorized as having no family history of prostate cancer, 
one family member with prostate cancer, and two or more family members with prostate cancer3.  The authors found 
that men with and without family history were re-categorized with higher grade cancer on follow up biopsy at 
similar frequencies (30.9% and 32.8%, respectively; p = 0.776).  When comparing patients who had one, two and 
three family members with prostate cancer, there did not appear to be a significant difference in men that were re-
categorized with higher grade cancer (p = 0.641).    
Similarly, Goh and colleagues examined 471 prostate cancer patients on active surveillance protocols4.  Of these 
patients, 55 had adverse pathology on repeat biopsies.  The authors found no significant relationship between family 
history of prostate cancer and adverse pathology (p = 0.154) and found no significant relationship between family 
history of prostate cancer and time to treatment.  The researchers further analyzed the DNA of 386 of the 471 
prostate cancer patients for 39 prostate cancer risk single nucleotide polymorphisms (SNPs) and calculated genetic 
risk scores of aggressive prostate cancer.  Analysis of genetic risk scores showed that there was no significant 
relationship between genetic risk scores and adverse pathology or time to treatment (p = 0.573 and p = 0.965, 
respectively).   
Iremashvili and colleagues found that family history was not a predictor of prostate cancer progression by following 
249 patients with prostate cancer on active surveillance protocols5.  Of the 249 patients, 64 patients showed a change 
to adverse pathology on surveillance biopsies and univariate analysis showed that family history was not a 
significant predictor of prostate cancer progression (p = 0.91).  Prostate cancer progression risk was, however, 
significantly higher in African American patients, regardless of family history (p < 0.001).  Pietzak and colleagues 
examined 468 patients with D’Amico low-risk disease who would have been eligible for active surveillance, but had 
immediate prostatectomy.  The authors examined the pathologic specimens in accordance with six different active 
surveillance criteria protocols6.  The authors found that African Americans were more likely to have adverse 
pathology if they met Prostate Cancer Research International: Active Surveillance Study (PRIAS) active 
surveillance criteria or met criteria for all six studied protocols.  Family history was only a significant predictor of 
prostate cancer progression among African American patients (p = 0.04).   
Impact of family history on serum biomarker findings 
Two observational studies used biomarkers, including PSA, to evaluate the relationship between family history of 
prostate cancer and cancer aggressiveness or progression in patients on active surveillance.  Lin and colleagues 
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followed 387 prostate cancer patients on active surveillance using PCA3 and TMPRSS2-ERG fusion biomarkers7.  
The authors found that family history of prostate cancer had no significant correlation with PCA3 and TMPRSS2-
ERG fusion biomarkers; therefore, family history was not an effective determinant of having aggressive cancer (p = 
0.28 and p = 0.37, respectively). Randazzo and colleagues sought to evaluate whether family history of prostate 
cancer was a risk factor for prostate cancer incidence, grade, and development of interval disease among men 
undergoing PSA screening for prostate cancer8.  Of the 610 patients who were found to have prostate cancer 
identified by PSA screening, a higher percent of men had a positive family history than had a negative family 
history (18.0% vs 12.0%, p < 0.01).  However, family history was not a significant predictor of finding aggressive 
cancer (p = 0.3) or of interval development of prostate cancer (p = 0.20). 
Discussion:  
We identified six peer-reviewed publications that evaluated the relationship between family history of prostate 
cancer and prostate cancer progression or aggressiveness.  Results from all six studies suggest that patients with and 
without a family history of prostate cancer have  no detectable differences in the probability of cancer progression 
while on active surveillance, with the exception of one study that found an increased risk of adverse pathologic 
features among African American men. Despite extensive investigations, most authors have been unable to 
demonstrate a relationship between family history and aggressiveness of disease. 
This review has several limitations.  First, we were only able to identify six relevant articles, although we believe 
that this is the totality of what has been published in English in PubMed.  The six articles also used two different 
definitions of disease progression, either biopsy-detected pathologic progression or serum biomarker-detected 
progression. Because of the limited number of studies, we were unable to create a unified definition of disease 
progression.  Finally, there was some suggestion in these publications that there may be a relationship between race, 
family history, and prostate cancer, but we were not able to fully examine this possible relationship because of the 
limited number of publications on this specific topic.  Additional research on the subject of race, family history, and 
eligibility for active surveillance is needed.  The relationship of family history to specific genetic markers for 
prostate cancer is also a subject of further inquiry11, 12.   
Notwithstanding these limitations, we think these findings have important implications for clinicians, patients and 
policymakers.  For clinicians, there does not appear to be enough evidence to support the use of family history as an 
exclusion criterion when considering men for active surveillance.  Physicians may need to make extra efforts to 
explain to patients and families that a positive family history does not require that patients be excluded from active 
surveillance.  However, for African American men, a positive family history may suggest an increased risk for more 
aggressive disease.  For policy makers, the limitations of these data and the possible relationship between family 
history and prostate cancer aggressiveness in African American men suggests a need to support additional 
prospective, large cohort studies of this subject.  
Conclusion:  
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According to our systematic review of relevant literature, a family history of prostate cancer does not appear to 
increase a patient’s risk of having more aggressive prostate cancer and should not be utilized as an absolute 
exclusion criterion for active surveillance treatment.  As always, individual decisions about the appropriateness of 
active surveillance treatments should be guided by shared decision-making between patients and their well-informed 
health care providers. 
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Table 
Table 1: Summary of Family History and Prostate Cancer Progression Publications 
Study Total number 
of patients 
% patients 
with + family 
history 
% patients with + 
family history and 
PC progression 
% patients without 
+ family history and 
PC progression 
P-value 
Studies that utilized pathologic findings to evaluate disease progression or risk 
Selkirk3 200 40.5  31.0 33.0 0.78 
Goh4 471 16.5 7.9 14.2 0.15 
Iremashvili5 249 17.7 25.0 25.8 0.91 
Pietzak6 468 
 
31.2 
 
na* na* >0.05 
 
Pietzak6 
Subset of 
African 
American 
patients 
66 28.8 47.8 22.2 0.04 
 
Studies that utilized biomarker findings to evaluate disease progression or risk 
Lin7 387 27.2 na^ na^ 0.28 
Randazzo8 610 9.8 4.2+ 3.1+ 0.20 
PC = Prostate cancer* = These specific values were not published for the combined set of African American and 
White American patients 
^
 = Results were published as median PCA3 and TMPRSS2:ERG scores 
+
 = Development of interval prostate cancer 
3
 = development of internal prostate cancer A
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